Quarterly ResultAug 13, 2026, 07:32 AM
CorMedix Q2 Revenue $101.9M; Raises FY26 Adj. EBITDA Guidance
AI Summary
CorMedix Inc. announced strong financial results for the second quarter of 2026, with consolidated revenue reaching $101.9 million and net income of $26.0 million. Adjusted EBITDA significantly increased to $58.7 million. The company maintained its full-year 2026 revenue guidance while raising its adjusted EBITDA guidance to a range of $125 million to $140 million. Additionally, CorMedix secured a new multi-year commercial supply agreement for DefenCath and anticipates submitting an sNDA for REZZAYO's expanded indication in Q3 2026.
Key Highlights
- Q2 2026 consolidated revenue was $101.9 million, up from $39.7 million in Q2 2025.
- Q2 2026 net income reached $26.0 million, or $0.33 basic EPS, compared to $19.8 million in Q2 2025.
- Q2 2026 adjusted EBITDA was $58.7 million, significantly up from $22.4 million in Q2 2025.
- DefenCath sales contributed $66.1 million, and the Melinta portfolio added $35.8 million to Q2 revenue.
- Company maintains FY 2026 revenue guidance of $325 million to $345 million.
- FY 2026 adjusted EBITDA guidance was raised to $125 million to $140 million.
- Signed a new multi-year commercial supply agreement for DefenCath with a Large Dialysis Operator.
- Anticipates FDA submission of REZZAYO sNDA for expanded indication in Q3 2026.
Price Impact
More from CRMD